These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29881595)

  • 1. No risk reduction for
    Moiz B; Majeed A
    Clin Case Rep; 2018 Jun; 6(6):1187-1188. PubMed ID: 29881595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.
    Poespoprodjo JR; Burdam FH; Candrawati F; Ley B; Meagher N; Kenangalem E; Indrawanti R; Trianty L; Thriemer K; Price DJ; Simpson JA; Price RN
    Lancet Infect Dis; 2022 Mar; 22(3):367-376. PubMed ID: 34710363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
    Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN
    Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of primaquine in malaria control and elimination in French-speaking Africa].
    Briolant S; Pradines B; Basco LK
    Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).
    Thriemer K; Degaga TS; Christian M; Alam MS; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Karahalios A; Rajasekhar M; Simpson JA; Rumaseb A; Mnjala H; Lee G; Anose RT; Kidane FG; Woyessa A; Baird K; Sutanto I; Hailu A; Price RN
    Trials; 2022 May; 23(1):416. PubMed ID: 35585641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review.
    Drysdale M; Tan L; Martin A; Fuhrer IB; Duparc S; Sharma H
    Infect Dis Ther; 2023 Jan; 12(1):33-51. PubMed ID: 36378465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation.
    Lek D; Tsai YC; Hirano J; Sovannaroth S; Bunreth V; Vonn P; Vannthen O; Bunkea T; Samphornarann T; Sokomar N; Sarath M; Kheang ST; Wong E; Burbach MK; Hughes J; Rekol H
    Malar J; 2024 Feb; 23(1):56. PubMed ID: 38395925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
    BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis.
    Shimizu S; Kikuchi T; Koga M; Kato Y; Matsuoka H; Maruyama H; Kimura M;
    Travel Med Infect Dis; 2015; 13(3):235-40. PubMed ID: 25482427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.
    Woon SA; Moore BR; Laman M; Tesine P; Lorry L; Kasian B; Yambo P; Yadi G; Pomat W; Batty KT; Salman S; Robinson LJ; Davis TME; Manning L
    Int J Infect Dis; 2023 May; 130():189-195. PubMed ID: 36906121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.
    Commons RJ; Simpson JA; Thriemer K; Hossain MS; Douglas NM; Humphreys GS; Sibley CH; Guerin PJ; Price RN
    Lancet Infect Dis; 2019 Jan; 19(1):91-101. PubMed ID: 30587297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of relapsing Plasmodium vivax malaria.
    Chu CS; White NJ
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):885-900. PubMed ID: 27530139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primaquine treatment for Plasmodium vivax--an essential tool for malaria control and elimination in Papua New Guinea.
    Betuela I; Robinson LJ; Hetzel MW; Laman M; Siba PM; Bassat Q; Mueller I
    P N G Med J; 2014; 57(1-4):68-74. PubMed ID: 26930890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.
    Pedro RS; Guaraldo L; Campos DP; Costa AP; Daniel-Ribeiro CT; Brasil P
    Malar J; 2012 Jul; 11():245. PubMed ID: 22839416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
    Hamid MMA; Thriemer K; Elobied ME; Mahgoub NS; Boshara SA; Elsafi HMH; Gumaa SA; Hamid T; Abdelbagi H; Basheir HM; Marfurt J; Chen I; Gosling R; Price RN; Ley B
    Malar J; 2018 Mar; 17(1):117. PubMed ID: 29548285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
    Taylor WRJ; Thriemer K; von Seidlein L; Yuentrakul P; Assawariyathipat T; Assefa A; Auburn S; Chand K; Chau NH; Cheah PY; Dong LT; Dhorda M; Degaga TS; Devine A; Ekawati LL; Fahmi F; Hailu A; Hasanzai MA; Hien TT; Khu H; Ley B; Lubell Y; Marfurt J; Mohammad H; Moore KA; Naddim MN; Pasaribu AP; Pasaribu S; Promnarate C; Rahim AG; Sirithiranont P; Solomon H; Sudoyo H; Sutanto I; Thanh NV; Tuyet-Trinh NT; Waithira N; Woyessa A; Yamin FY; Dondorp A; Simpson JA; Baird JK; White NJ; Day NP; Price RN
    Lancet; 2019 Sep; 394(10202):929-938. PubMed ID: 31327563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
    Wångdahl A; Sondén K; Wyss K; Stenström C; Björklund D; Zhang J; Hervius Askling H; Carlander C; Hellgren U; Färnert A
    Clin Infect Dis; 2022 Apr; 74(7):1199-1207. PubMed ID: 34216464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declining Burden of
    Chu CS; Carrara VI; Parker DM; Proux S; Charunwatthana P; McGready R; Nosten F
    Am J Trop Med Hyg; 2020 Jan; 102(1):147-150. PubMed ID: 31746312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primaquine treatment and relapse in Plasmodium vivax malaria.
    Rishikesh K; Saravu K
    Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
    Rajasekhar M; Simpson JA; Ley B; Edler P; Chu CS; Abreha T; Awab GR; Baird JK; Bancone G; Barber BE; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thriemer K; Watson JA; Guerin PJ; White NJ; Price RN; Commons RJ;
    Lancet Infect Dis; 2024 Feb; 24(2):184-195. PubMed ID: 37748497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.